helen,
l find yr experiences with MS drugs disturbing. l've had MS 15 yrs, yet have only taken MS drugs for 3.5 yrs. l took myself off them yrs ago because l was only ever having MS episodes whilst on them, which didn't make sense. mind u, my neuro was full of doom and gloom but that officious individual cannot dispute the facts, although l'm sure he would love to!
l'm off to have a second colonic today - the first did not work at all, so wish me luck...my eyeballs will turn brown soon otherwise... cheers, nico
CCSVI - Aussie Action!
reactivity to drugs
Helen and Jennifer,
thankyou both for yr kind words and feedback - l really appreciate it.
cheers, nico
thankyou both for yr kind words and feedback - l really appreciate it.
cheers, nico
-
CureOrBust
- Family Elder
- Posts: 3374
- Joined: Wed Jul 27, 2005 2:00 pm
- Location: Sydney, Australia
Re: do MS drugs actually work?
Have you tried high dose Magnesium Oxide? There is a product you can buy online in powder form. They talk of people taking up to 20 spoonfulls (cancer patients) with lemon juice. I tried it as part of the "Vonner" protocol, and it certainly has a "definitive clearing effect". Jimmylegs finds that a few magnesium supplements (most commonly magnesium oxide) are too many for her.nico wrote:l'm off to have a second colonic today - the first did not work at all, so wish me luck...my eyeballs will turn brown soon otherwise...
Re: do MS drugs actually work?
howdy, can't take laxatives at all i'm afraid 'cos, cop this, they have the OPPOSITE effect. l have had some success today as l've been subsisting on boiled brown rice, steamed silver beet, etc - as per the instructions of a highly competent naturopath. cheers and thank you for yr interest! NicoCureOrBust wrote:Have you tried high dose Magnesium Oxide? There is a product you can buy online in powder form. They talk of people taking up to 20 spoonfulls (cancer patients) with lemon juice. I tried it as part of the "Vonner" protocol, and it certainly has a "definitive clearing effect". Jimmylegs finds that a few magnesium supplements (most commonly magnesium oxide) are too many for her.nico wrote:l'm off to have a second colonic today - the first did not work at all, so wish me luck...my eyeballs will turn brown soon otherwise...
didn't know how to just paste blasted link - SORRY!
NEUROLOGY 2010;74:1041-1047
© 2010 American Academy of Neurology
Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis
R.A. Marrie, MD, PhD, R. Rudick, MD, R. Horwitz, MD, G. Cutter, PhD, T. Tyry, PhD, D. Campagnolo, MD and T. Vollmer, MD
From the Department of Medicine (R.A.M.), University of Manitoba, Winnipeg, Canada; Neurological Institute (R.R.), Cleveland Clinic, Cleveland, OH; Department of Medicine (R.H.), Stanford University, Stanford, CA; Department of Biostatistics (G.C.), University of Alabama at Birmingham; and Division of Neurology (T.T., D.C., T.V.), Barrow Neurological Institute, Phoenix, AZ.
Address correspondence and reprint requests to Dr. Ruth Ann Marrie, Health Sciences Center, GF-533, 820 Sherbrook Street, Winnipeg, MB R3A 1R9, Canada rmarrie@hsc.mb.ca.
Background: Vascular comorbidity adversely influences health outcomes in several chronic conditions. Vascular comorbidities are common in multiple sclerosis (MS), but their impact on disease severity is unknown. Vascular comorbidities may contribute to the poorly understood heterogeneity in MS disease severity. Treatment of vascular comorbidities may represent an avenue for treating MS.
Methods: A total of 8,983 patients with MS enrolled in the North American Research Committee on Multiple Sclerosis Registry participated in this cohort study. Time from symptom onset or diagnosis until ambulatory disability was compared for patients with or without vascular comorbidities to determine their impact on MS severity. Multivariable proportional hazards models were adjusted for sex, race, age at symptom onset, year of symptom onset, socioeconomic status, and region of residence.
Results: Participants reporting one or more vascular comorbidities at diagnosis had an increased risk of ambulatory disability, and risk increased with the number of vascular conditions reported (hazard ratio [HR]/condition for early gait disability 1.51; 95% confidence interval [CI] 1.41–1.61). Vascular comorbidity at any time during the disease course also increased the risk of ambulatory disability (adjusted HR for unilateral walking assistance 1.54; 95% CI 1.44–1.65). The median time between diagnosis and need for ambulatory assistance was 18.8 years in patients without and 12.8 years in patients with vascular comorbidities.
Conclusions: Vascular comorbidity, whether present at symptom onset, diagnosis, or later in the disease course, is associated with a substantially increased risk of disability progression in multiple sclerosis. The impact of treating vascular comorbidities on disease progression deserves investigation.
Abbreviations: EDSS = Expanded Disability Status Scale; HR = hazard ratio; MS = multiple sclerosis; NARCOMS = North American Research Committee on Multiple Sclerosis; PDDS = Patient Determined Disease Steps.
Study funding: Supported in part by the NIH, National Institute of Child Health and Human Development, and Multidisciplinary Clinical Research Career Development Program Grant K12 HD04909. The NARCOMS Registry is supported by the Consortium of Multiple Sclerosis Centers.
Disclosure: Author disclosures are provided at the end of the article.
Received September 17, 2009. Accepted in final form January 6, 2010.
* Home
* Browse
* For Authors
* Residents & Fellows
* Patients
* CME
* Correspondence
* International
* AAN.com
Copyright © 2010 by AAN Enterprises, Inc.
Online ISSN: 1526-632X
Lippincott Williams & Wilkins HighWire®
© 2010 American Academy of Neurology
Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis
R.A. Marrie, MD, PhD, R. Rudick, MD, R. Horwitz, MD, G. Cutter, PhD, T. Tyry, PhD, D. Campagnolo, MD and T. Vollmer, MD
From the Department of Medicine (R.A.M.), University of Manitoba, Winnipeg, Canada; Neurological Institute (R.R.), Cleveland Clinic, Cleveland, OH; Department of Medicine (R.H.), Stanford University, Stanford, CA; Department of Biostatistics (G.C.), University of Alabama at Birmingham; and Division of Neurology (T.T., D.C., T.V.), Barrow Neurological Institute, Phoenix, AZ.
Address correspondence and reprint requests to Dr. Ruth Ann Marrie, Health Sciences Center, GF-533, 820 Sherbrook Street, Winnipeg, MB R3A 1R9, Canada rmarrie@hsc.mb.ca.
Background: Vascular comorbidity adversely influences health outcomes in several chronic conditions. Vascular comorbidities are common in multiple sclerosis (MS), but their impact on disease severity is unknown. Vascular comorbidities may contribute to the poorly understood heterogeneity in MS disease severity. Treatment of vascular comorbidities may represent an avenue for treating MS.
Methods: A total of 8,983 patients with MS enrolled in the North American Research Committee on Multiple Sclerosis Registry participated in this cohort study. Time from symptom onset or diagnosis until ambulatory disability was compared for patients with or without vascular comorbidities to determine their impact on MS severity. Multivariable proportional hazards models were adjusted for sex, race, age at symptom onset, year of symptom onset, socioeconomic status, and region of residence.
Results: Participants reporting one or more vascular comorbidities at diagnosis had an increased risk of ambulatory disability, and risk increased with the number of vascular conditions reported (hazard ratio [HR]/condition for early gait disability 1.51; 95% confidence interval [CI] 1.41–1.61). Vascular comorbidity at any time during the disease course also increased the risk of ambulatory disability (adjusted HR for unilateral walking assistance 1.54; 95% CI 1.44–1.65). The median time between diagnosis and need for ambulatory assistance was 18.8 years in patients without and 12.8 years in patients with vascular comorbidities.
Conclusions: Vascular comorbidity, whether present at symptom onset, diagnosis, or later in the disease course, is associated with a substantially increased risk of disability progression in multiple sclerosis. The impact of treating vascular comorbidities on disease progression deserves investigation.
Abbreviations: EDSS = Expanded Disability Status Scale; HR = hazard ratio; MS = multiple sclerosis; NARCOMS = North American Research Committee on Multiple Sclerosis; PDDS = Patient Determined Disease Steps.
Study funding: Supported in part by the NIH, National Institute of Child Health and Human Development, and Multidisciplinary Clinical Research Career Development Program Grant K12 HD04909. The NARCOMS Registry is supported by the Consortium of Multiple Sclerosis Centers.
Disclosure: Author disclosures are provided at the end of the article.
Received September 17, 2009. Accepted in final form January 6, 2010.
* Home
* Browse
* For Authors
* Residents & Fellows
* Patients
* CME
* Correspondence
* International
* AAN.com
Copyright © 2010 by AAN Enterprises, Inc.
Online ISSN: 1526-632X
Lippincott Williams & Wilkins HighWire®
nothing to do with CCSVI?
hi all, the above condition may have zip to do with CCSVI. bheers
it does fit actually
hi all,
did some hunting - CCSVI is indeed a vascular condition which makes a co-existing disease likjew MS worse. it fits the definition...cheers, nico
did some hunting - CCSVI is indeed a vascular condition which makes a co-existing disease likjew MS worse. it fits the definition...cheers, nico
-
CureOrBust
- Family Elder
- Posts: 3374
- Joined: Wed Jul 27, 2005 2:00 pm
- Location: Sydney, Australia
Re: do MS drugs actually work?
Its not a "laxative", but I can understand your weariness; you know your body best.nico wrote:howdy, can't take laxatives at all i'm afraid 'cos, cop this, they have the OPPOSITE effect.
at last
hi all,
had a third procedure (private patient, not our guru, Prof T)last Tues and haven't taken any aspirin like l did after the second op. Both jugs had restenosed in response to the aspirin. l can state that with certainty 'cos my left jug (opened during my first op in March stayed open for 3 months with no probs until l took the aspirin. WEIRD!)Absolutely ecstatic to report my feet are warm, bowels work, no pain etc. gosh, if l walk again, it'll be the icing on my cake! We are so lucky.
cheers, ALL THE VERY BEST to everyone, Nico
had a third procedure (private patient, not our guru, Prof T)last Tues and haven't taken any aspirin like l did after the second op. Both jugs had restenosed in response to the aspirin. l can state that with certainty 'cos my left jug (opened during my first op in March stayed open for 3 months with no probs until l took the aspirin. WEIRD!)Absolutely ecstatic to report my feet are warm, bowels work, no pain etc. gosh, if l walk again, it'll be the icing on my cake! We are so lucky.
cheers, ALL THE VERY BEST to everyone, Nico
Re: at last
Wow, that's excellent! Congrats! Best wishes for continued improvement.nico wrote:Absolutely ecstatic to report my feet are warm, bowels work, no pain etc. gosh, if l walk again, it'll be the icing on my cake! We are so lucky.
Re: at last
Wow, that's excellent! Congrats! Best wishes for continued improvement.[/quote]
thank you Rokkit!
cheers, the warm-footed one.
thank you Rokkit!
cheers, the warm-footed one.
My last procedure didn't go so well. i am feeling pretty fed up.an answer!
Val,
l've answered! cheers, nico
l've answered! cheers, nico
-
hwebb
- Family Elder
- Posts: 361
- Joined: Thu Nov 26, 2009 3:00 pm
- Location: Melbourne, Australia
- Contact:
hooray Nico!
Nico,
that's great news! It's interesting about the asprin. They say asprin is very hard on the stomach lining. Wonder if the same is true for the vein lining (the endothelium)? Maybe another anticoagulant would be gentler (say an omega-3 agent like fish oil). Just thinking aloud here. Sounds like you had better results using no coagulant at all. Wish they could do a test before the angioplasty to see which after-care is likely to be best for each patient.
Helen
that's great news! It's interesting about the asprin. They say asprin is very hard on the stomach lining. Wonder if the same is true for the vein lining (the endothelium)? Maybe another anticoagulant would be gentler (say an omega-3 agent like fish oil). Just thinking aloud here. Sounds like you had better results using no coagulant at all. Wish they could do a test before the angioplasty to see which after-care is likely to be best for each patient.
Helen